Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Home, PD; Pocock, SJ; Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Jones, NP; Komajda, M; McMurray, JJV; Team, RS; (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 373 (9681). pp. 2125-2135. ISSN 0140-6736 DOI: https://doi.org/10.1016/S0140-6736(09)60953-3

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S0140-6736(09)60953-3

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar